A Computational Approach to Evaluate the Androgenic Affinity of Iprodione, Procymidone, Vinclozolin and Their Metabolites

Corrado Lodovico Galli*, Cristina Sensi*, Amos Fumagalli, Chiara Parravicini, Marina Marinovich, Ivano Eberini

Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italia

Abstract

Our research is aimed at devising and assessing a computational approach to evaluate the affinity of endocrine active substances (EASs) and their metabolites towards the ligand binding domain (LBD) of the androgen receptor (AR) in three distantly related species: human, rat, and zebrafish. We computed the affinity for all the selected molecules following a computational approach based on molecular modelling and docking. Three different classes of molecules with well-known endocrine activity (iprodione, procymidone, vinclozolin, and a selection of their metabolites) were evaluated. Our approach was demonstrated useful as the first step of chemical safety evaluation since ligand-target interaction is a necessary condition for exerting any biological effect. Moreover, a different sensitivity concerning AR LBD was computed for the tested species (rat being the least sensitive of the three). This evidence suggests that, in order not to over- and/or under-estimate the risks connected with the use of a chemical entity, further in vitro and/or in vivo tests should be carried out only after an accurate evaluation of the most suitable cellular system or animal species. The introduction of in silico approaches to evaluate hazard can accelerate discovery and innovation with a lower economic effort than with a fully wet strategy.

Introduction

During the last years, following some evidence suggesting that exposure to environmental chemicals can lead to disruption of endocrine function in a number of wildlife species (molluscs, crustacean, fish, and birds), concern has been expressed also for human health. Even if many EU regulations contain specific provisions on chemicals that can affect the endocrine system, (e.g. REACH [1], Plant Protection Products Regulation [2], Biocides Regulation [3], Regulation on cosmetics [4], Water Framework Directive [5]), warning was raised by Bars et al. [6], who stated that recent European legislation has created a hazard-based approval criterion, which supports marketing and use of chemicals only on the basis that they do not induce endocrine activation in humans or wildlife species.

The in silico approaches have become relevant to these legislations as far as they can help reduce the number of animals used (by pre-screening and prioritising chemicals for more intensive testing). Moreover, they are in line with the vision of the 21st century toxicity paradigm: chemicals will be subjected to a multiplicity of high-throughput screening tests to detect cellular response to an array of “pathways of toxicity”, and results will feed into computational systems biology tools that model dose-response effects and inform new risk assessment approaches [7]. Several computational approaches may be useful for evaluating interactions between a receptor and its putative ligands: some of them are based on molecular docking, which has been reliably used for decades in pharmacological research and development [8,9].

The present research is aimed at devising and assessing a computational approach to evaluate the affinity towards the androgen receptor (AR) of hormonally active substances and of their metabolites. To build the model, the ligand binding domain (LBD) structures of ARs of three distantly related species (human, rat, and zebrafish) were used. The use of three reference species was also meant to evaluate whether their sensitivities to the test chemicals do differ. Three fungicides (vinclozolin, iprodione and procymidone) and their rat metabolites [10–13], all with a well-established androgenic activity [14–18], were tested. The proposed model can anticipate, very early in the hazard identification procedure, the ability of a chemical to bind the AR LBD. This information is very useful to set up a priority list during the screening of a large chemical database, and may be exploited also to design new chemicals for use in different fields [19]. To date, considering the available tests, evidence coming just from in silico assays cannot be considered sufficient for the identification of an endocrine-active substance, and the assessment of its possible relevance to humans. However, the information
about qualitative and quantitative hormonal response to a chemical might be useful to identify its potential for interaction with the endocrine system, and therefore to better design and carry out further testing steps.

Materials and Methods

Comparative modeling

The human and rat AR LBD crystal structures were downloaded from the RCSB Protein Data Bank [PDB entry: 3L3X (chain A), and PDB entry: 1I37, respectively]. The crystallographic structures of the human and rat receptors were then submitted to a preparation step, based on energy minimization (EM) with the Amber12:EHT force field [20] and the reaction field solvation model. Refinement was carried out down to a Root Mean Square (RMS) gradient of 0.05 kcal/mol/Å². All the computational procedures were carried out with the Molecular Operating Environment (MOE).

The zebrafish AR sequence was downloaded from the UniProt Protein Knowledgebase database [entry: B9P3Q2], 1T7R, corresponding to the chimpanzee AR LBD, was set as template in order to compute a 3D structural model [21]. The alignment produced by the MOE Align program with default parameters was manually adjusted. Comparative model building was carried out with the MOE Homology Model program. Ten independent models were built and refined, then the highest scoring intermediate model - according to the electrostatic solvation energy calculated using a Generalized Born/Volume Integral (GB/VI) methodology [22] - was submitted to a further round of EM. Both for the intermediate and the final structures, the refinement procedures consisted in EM runs based on the Amber12:EHT force field with the reaction field solvation model. The quality of the final model was carefully checked with the MOE Protein Geometry module, in order to make sure that the Ramachandran plot, the side chain packing, and the stereochemical quality of the generated structure were acceptable.

Binding site analysis

The binding site of each receptor was identified through the MOE Site Finder module, confirmed the binding sites defined by the co-crystallized ligands in the holo-forms of the investigated proteins.

Molecular database preparation

The database was prepared by building with the MOE Builder the molecular structures of the three fungicides and of their major rat metabolites, as well as the molecular structures of the endogenous hormones in each species (human, rat and zebrafish). Each structure was converted into a tridimensional structure, and energy was minimized, with the MOE Energy Minimize program and the Amber12:EHT force field, down to a RMS gradient of 0.05 kcal/mol/Å². Since some of these molecules contain stereogenic centres (see Figure 1, atoms marked by an asterisk), all the possible enantiomers/diastereomers were built and added to the database. Moreover, 20,000 conformations were generated for each ligand by sampling all their rotatable bonds.

Molecular docking

The in silico screening was carried out with the MOE Dock program, part of the MOE Simulation module. The whole procedure was carried out for each of the three AR LBD - human, rat and zebrafish. The AR LBD was set as ‘Receptor’. The selected placement methodology was ‘Triangle Matcher’, which is the best method for standard and well-defined binding sites. With Triangle Matcher the poses are generated by superposing triplets of ligand atoms and triplets of receptor site points. The receptor site points are alpha spheres centres that represent locations of tight packing. Thirty complexes were generated for each tested ligand. Duplicate complexes were then removed: poses are considered as duplicates if the same set of ligand-receptor atom pairs are involved in hydrogen bond interactions and the same set of ligand atom receptor residue pairs are involved in hydrophobic interactions. The accepted poses were scored according to the London dG scoring function, which estimates the binding free energy of the ligand from a given pose.

\[
AG = c + E_{\text{flex}} + \sum_{h\text{-}bonds} c_{\text{HB}} + \sum_{m\text{-}lig} c_{\text{M}} + \sum_{\text{atoms, }i} \Delta D_i
\]

where \(c\) represents the average gain/loss of rotational and translational entropy; \(E_{\text{flex}}\) is the energy due to the loss of flexibility of the ligand (calculated from ligand topology only); \(f_{\text{HB}}\) measures geometric imperfections of hydrogen bonds and takes a value in \([0,1]\); \(e_{\text{HB}}\) is the energy of an ideal hydrogen bond; \(f_{\text{M}}\) measures geometric imperfections of metal liggations and takes a value in \([0,1]\); \(c_{\text{M}}\) is the desolvation energy of atom \(i\). The difference in desolvation energies is calculated according to the formula

\[
\Delta D_i = c_i R^3 \left[ \int_{u|A \cap u|B} |u|^{-6} \, du - \int_{u|A \cap u|B} |u|^{-6} \, du \right]
\]

where \(A\) and \(B\) are the protein and/or ligand volumes with atom \(i\) belonging to volume \(B\); \(R\) is the solvation radius of atom \(i\) (taken as the OPLS-AA van der Waals sigma parameter plus 0.5 Å); and \(c_i\) is the desolvation coefficient of atom \(i\). The coefficients \(c, c_{\text{HB}}, c_{\text{M}}, c_i\) have been fitted from approx. 400 x-ray crystal structures of protein–ligand complexes with available experimental \(pK_a\) data. Atoms are categorized into about a dozen types for the assignment of the \(c_i\) coefficients. The triple integrals are approximated using Generalized Born integral formulas.

All the saved solutions were submitted to a further refinement step, based on molecular mechanics (MM). In order to speed up the calculation, residues over 6 Å cutoff distance away from the pre-refined pose were ignored, both during the refinement and in the final energy evaluation. All receptor atoms were held fixed during the refinement. During the course of the refinement, solvation effects were calculated using the reaction field functional form for the electrostatic energy term. The final energy, docking score, was evaluated using the GBVI/WSA dG scoring function with the Generalized Born solvation model (GBVI) [24]. The GBVI/WSA dG is a forcefield-based scoring function, which estimates the free energy of binding of the ligand from a given pose. It has been trained using the MMFF94x and AMBER99 forcefields on the 99 protein-ligand complexes of the Solvated Interaction Energy (SIE) training set [25]. The functional form is a sum of terms:
\[ \Delta G \approx c + \alpha \left[ \frac{2}{3}(\Delta E_{\text{coul}} + \Delta E_{\text{sol}}) + \Delta E_{\text{vdw}} + \beta \Delta S_{\text{weighted}} \right] \] (3)

where \( c \) represents the average gain/loss of rotational and translational entropy. \( \alpha \) and \( \beta \) are constants, which were determined during training (along with \( c \)) and are forcefield-dependent. \( E_{\text{coul}} \) is the coulombic electrostatic term, which is calculated using currently loaded charges, using a constant dielectric of 1. \( E_{\text{sol}} \) is the solvation electrostatic term, which is calculated using the GB/VI solvation model. \( E_{\text{vdw}} \) is the van der Waals contribution to binding. \( S_{\text{weighted}} \) is the surface area

Figure 1. 2D structures of the molecules used to build the test database. The stereogenic centres are marked with an asterisk (*). Each molecule is marked by a letter: A = testosterone, B = dihydrotestosterone (DHT), C = 11-ketotestosterone, D = vinclozolin, E = vinclozolin_1, E = vinclozolin_2, F = vinclozolin_5, H = iprodione, I = iprodione_8, J = iprodione_13, K = iprodione_14, L = procymidone, M = procymidone_1, N = procymidone_2, O = procymidone_3, P = procymidone_4, Q = procymidone_5, R = procymidone_6, S = cyproterone acetate, T = flutamide, U = procymidone-NH-COOH, V = procymidone-3-Cl, W = cyclopropane-(COOH)_2.

doi:10.1371/journal.pone.0104822.g001
weighted by exposure. This weighting scheme penalizes exposed surface area. All the ligands of the molecular database were tested according to the above procedure. The Amber12:EHT force field was used for all the computational procedures.

Docking accuracy was evaluated using the present procedure for reproducing 10 ligand-receptor crystallographic complexes. Ligand RMSD values between crystallographic vs computational complexes were measured.

As a negative dataset, we randomly selected 1,000 compounds from the Asinex Platinum Database (http://www.asinex.com) and docked them on the human AR LBD, using the above procedure.

Low-mode molecular dynamics simulations

For studying the flexibility of AR LBD helix 12, we applied the low-mode molecular dynamics approach, aimed at focusing a MD trajectory along the low-mode vibrations and featuring a very efficient way to classical MD for searching for minima troughs on the potential energy surface. To run these computations, we used the MOE Conformational Search program of the Conformations module. This program uses an efficient implicit method for estimating the low-frequency modes and is based on the attenuation of high-range velocities as described in detail in [26].

The human AR LBD bound to: i) dihydrotestosterone (DHT), an agonist, ii) cyproterone acetate, an antagonist, and iii) in its apo form was simulated after preparation. The complex with DHT was obtained from RCSB PDB (3L3X); the apo form was obtained by in silico removing DHT, and the complex with cyproterone acetate was obtained through molecular docking on the same crystal structure.

Both helix 12 (set as a rigid body) and the loop joining helix 12 to the preceding helix were left free to move during the low-mode molecular dynamics, whereas the residues more than 4.5 Å away were fixed (not free to move, but used for the energy calculations); the other residues were defined as inert (fixed and not used for energy calculations). The simulation was carried out with default parameters, except for strain energy cutoff, which was set at 100 kcal/mol. One thousand conformations were generated and analysed.

The same computational approach was used also to produce ensembles of natural ligand-receptor complexes, in order to estimate with greater accuracy their binding free energies. To this purpose, we started from the top scoring poses obtained from the molecular docking procedure. The ligand and the residues within 4.5 Å from it were left free to move during the low-mode molecular dynamics, whereas the residues more than 4.5 Å away were fixed (see above); the other residues were defined as inert (see above). The simulation was carried out with default parameters, except for strain energy cutoff, which was set at 50 kcal/mol. Four hundred conformations were generated and the one with the lowest energy was used to compute the complex dissociation constant value. The Amber12:EHT force field was used for all the computational procedures.

Dissociation constant calculation

The estimated binding affinity of the top-scoring solution for each complex (receptor-ligand) was not directly computed from the GBVI/WSA dG value, but the complexes were further refined through the use of a set of specific MOE procedures, named LigX, aimed at the minimization of ligands in the receptor binding site. The dissociation constant ($K_d$) was computed through the binding free energy estimated with the GBVI/WSA dG scoring function, after complex optimization with LigX, according to the following equation:

$$\Delta G = RT\ln(K_d)$$  \hspace{1cm} (4)

where $R$ represents the gas constant and $T$ the temperature. The $K_d$ was computed starting from the binding free energy values at a fixed temperature (300 K).

Results

Comparative modeling

The homology model of the zebrafish AR LBD was built using as template 1T7R, the crystal structure of chimpanzee AR LBD (66% sequence identity). Figure S1 in File S1 shows the alignment used for carrying out the modelling procedure. Ten independent models were built and refined, and the one top scoring according to the electrostatic solution energy was selected. The presence of a well-defined binding site, shown in Figure 2, was probed through the MOE Site Finder program. The same approach was applied to human and rat AR LBD crystals. Table 1 reports the binding site scores for the three receptor structures and lists the residues lining each of them. Figure 3 shows the global alignment of the investigated AR LBD; the residues in the binding sites are highlighted. Finally, after a structural superposition, the global and the binding site RMSD values were computed both for $\alpha$-carbons and for whole residues of the three AR LBD; data are summarized in Table 2.

Validation of the docking protocol

The accuracy of the docking protocol detailed under Methods was extensively validated by reproducing the ligand-receptor complexes for 10 different AR LBDs deposited in the RCSB PDB. Table 3 reports the selected structures and the RMSD values between the co-crystallized and the docked ligands: the latter range between 0.13 and 0.35 Å.

In order to assess the correlation between docking scores and biological data, we docked to the rat AR LBD seven ligands from a published dataset, whose relative affinities for the rat AR binding site had been experimentally determined [27]. The computed relative affinities (dissociation constants, $K_d$) showed the same ranking as the experimental ones; Table 4 reports experimental (literature data) vs in silico (our computations) data.

Furthermore, from an Asinex combinatorial chemistry dataset, we randomly selected 1,000 compounds, which have never been predicted/demonstrated to bind AR LBDs, and evaluated their docking score on the human AR. All of their docking scores were positive ($>0$, as plotted in Figure S2 in File S1), which substantiates the ability of the proposed procedure to correctly identify negative (non-interacting) compounds.

Results of docking the test compounds to zebrafish, rat and human AR LBD

Figure 1 reports the structures of the three parent test fungicides and of their selected metabolites. The molecular database also contains the main endogenous androgenic hormones for all the three species, namely testosterone and DHT for human and rat [28], testosterone and 11-ketotestosterone for zebrafish [29].

Table 5 reports the dissociation constants ($K_d$) of ligands from the ASINEX Platinum database (http://www.asinex.com) vs the hormones, (S)-vinclozolin and (R)-vinclozolin show an intermediate affinity ($-9.87$ kcal/mol and $-9.61$ kcal/mol, respectively), whereas their metabolites, (R)-vinclozolin_1 and (S)-vinclozolin_1, show the second ($-10.80$ kcal/mol) and the
fourth highest affinity (−10.44 kcal/mol), respectively. Iprodione shows the highest affinity (−11.35 kcal/mol) for human AR, whereas procymidone one of the lowest (−9.27 kcal/mol). The Docking Scores reported in Table 6 were used to build the box plot reported in Figure 4.

Taking as thresholds the affinities for the endogenous hormones [30,31], five molecules, iprodione, (R)-vinclozolin_1, (R,S)-procymidone_1, (S)-vinclozolin_1 and (S,S)-procymidone_1, show a higher affinity for human AR than testosterone (−10.30 kcal/mol) (Figure 4, human, green line), while only two molecules, iprodione_14 and iprodione_13, have a lower affinity (Figure 4, human, pink line) than DHT (−9.11 kcal/mol).

In rat, iprodione and its metabolites have the lowest affinity (higher Docking Score) for AR: iprodione_13 (J), −6.93 kcal/mol, and iprodione_14 (K) −7.21 kcal/mol, rank worse than the parent molecule iprodione (−8.94 kcal/mol). The affinity varies extensively among molecules derived from procymidone: (R)-procymidone_6 (R), −9.65 kcal/mol, and (R,R)-procymidone_3 (O), −9.67 kcal/mol, have a favourable binding energy, contrary to the parent compound, procymidone (L), −8.31 kcal/mol. Compared with their metabolites, (S)-vinclozolin and (R)-vinclozolin show low affinities for rat AR: −8.22 kcal/mol and −8.18 kcal/mol, respectively. Finally, the binding energies of the endogenous hormones are the lowest (most favourable) among the tested molecules: testosterone, −10.40 kcal/mol, and DHT, −10.97 kcal/mol.

In zebrafish, procymidone metabolites vary extensively in energy: (R,R)-procymidone_3 (O) has the best affinity (−11.06 kcal/mol), but procymidone_4 (P) has the third worst energy (−8.52 kcal/mol), and the parent compound has a low affinity (−8.49 kcal/mol) for AR.

As in rat, (R)-vinclozolin, −9.12 kcal/mol, and (S)-vinclozolin, −8.73 kcal/mol, are in the low ranking positions. Also iprodione, −9.74 kcal/mol, and its metabolites show low affinity for zebrafish AR: the molecule with the lowest affinity is iprodione_13 (J), −8.38 kcal/mol.

Using hormone affinity as threshold, four molecules, all procymidone metabolites, (R,R)-procymidone_3, (S)-procymidone_6, (R,R)-procymidone_2, (S,R)-procymidone_1, display a better affinity than 11-ketotestosterone (−10.29 kcal/mol), while testosterone shows a slightly lower affinity (−10.21 kcal/mol).

Only for exemplification purposes, Figure 5 reports the top scoring poses for iprodione complexed with human (A), rat (B), and zebrafish (C) AR, respectively; iprodione orientation appears similar in the three complexes, with a RMSD value of 0.8 Å between human and zebrafish, and 1.9 Å between rat and zebrafish.
are very low. Our in silico approach does not take into account the receptor rearrangement and this results in higher values for computed \( K_s \).

Low-mode molecular dynamics simulations of AR LBDs were then run, under different computational setups, with a twofold aim: i) sampling the conformational space of helix 12 in the human AR LBD, when bound to an agonist and to an antagonist, and in its apo form; ii) estimating binding affinities of the natural hormones for the three AR LBDs at a higher accuracy level than with molecular docking. During the molecular dynamics simulations, helix 12 keeps a closed conformation when the human AR binds an agonist (DHT), whereas it opens when the LBD is empty or bound to an antagonist (cyproterone acetate). Starting from a common closed conformation of helix 12 in all the three setups, only the apo and the antagonist-bound structures rapidly evolve towards helix 12 opening. Figure 6 shows the three closed starting conformations (helix 12), superposed to the most energetically favoured open conformation for the apo (Figure 6, panel B) and the antagonist-bound LBD (Figure 6, panel C). On the contrary, helix 12 does not open (1,000 generated and analysed conformations) when LBD is bound to an AR agonist, such as DHT (Figure 6, panel A).

In spite of the ability of molecular dynamics to correctly sample the reported helix 12 conformational transition, the differences between experimental and computational dissociation constant values for natural agonists cannot yet be compensated for. Indeed, as shown in Table 5, the binding affinities of the natural hormones for the three investigated LBDs, computed applying LigX to the lowest energy complex out of 400 obtained from the low-mode molecular dynamics simulations, are very close to the affinities obtained from our rapid docking procedure. The experimental issue is connected with the definition of \( K_i \) as the ratio \( k_{off}/k_{on} \), where \( k_{off} \) is the dissociation rate constant in \( \text{min}^{-1} \) and \( k_{on} \) is the association rate constant in \( \text{M}^{-1} \text{min}^{-1} \). The closed conformation of helix 12 induced by the binding of an agonist produces a decrease in \( k_{off} \) values, thus reducing the apparent dissociation constant. The discrepancy between experimental and computational \( K_i \) for the tested natural agonists is strictly connected with this phenomenon. The analysis of the interactions between helix 12 and DHT, carried out on a crystallographic complex (RCSB PDB code: 3L3X), shows only one weak and non-specific interaction between the ligand and the side chain of Met 895, in helix 12 (see Figure S3 in File S1), corroborating a kinetic more than a thermodynamic effect as the reason for the discrepancy between computed and experimental \( K_s \).

**Discussion**

Traditional in vitro and in vivo toxicity-testing strategies, which are expensive and time consuming and involve a large number of test animals, have been evolving over the last few decades, in order to address increasing concerns about a wider variety of toxic responses, such as subtle neurotoxic effects, adverse immunologic changes, and endocrine activity. Moreover, toxicity testing is under increasing pressure, and the most utilized approach, which

---

**Table 2.** AR LBD and binding site RMSD values, computed for \( \alpha \)-carbons and for whole residues of the three selected receptors.

|                | RMSD C alpha [Å] | RMSD All atoms [Å] |
|----------------|------------------|--------------------|
| AR LBD         | 1.27             | 1.52               |
| Binding site   | 0.59             | 0.77               |

doi:10.1371/journal.pone.0104822.t002
relies primarily on in vivo mammalian toxicity testing, is unable to adequately meet the competing demands [35].

Although the current knowledge may not yet allow to fully eliminating the need for in vivo testing, our proposed computational approach, associated with suitable in vitro assays, can provide an effective tool to identify, at a very early stage, the potential of any EAS, through the measurement of its affinity (the binding free energy/complex $K_i$) for the AR. This kind of information can be useful at the very beginning of the pipeline of hazard identification for compounds with putative EAS activity. The direct interaction between the putative EAS and the AR is a prerequisite to biological activity and should be carefully kept into account, as done in our model. Interaction depends principally upon affinity, which is a term referring to the strength of interaction between two molecules. The affinity of a ligand for a specific receptor determines its residence time of association, a parameter often quantified by the dissociation constant [36].

The direct interaction between the putative EAS and the AR is a prerequisite to biological activity and should be carefully kept into account, as done in our model. Interaction depends principally upon affinity, which is a term referring to the strength of interaction between two molecules. The affinity of a ligand for a specific receptor determines its residence time of association, a parameter often quantified by the dissociation constant [36]. Generally, the higher is the affinity the longer is the residence time. Low affinity ligands do not need any evaluation of intrinsic activity ($\alpha$, which is the relative ability of a drug-receptor complex to produce a maximum functional response), since they do not spend enough time in the receptor binding site to exert any effect either in vitro or in vivo tests.

Although interaction between ligand and receptor is essential in order to cause any effect, the intrinsic activity is the key to the ability of a molecule to induce a specific response. For the molecules with in silico high affinity for ARs, in vitro selected tests should first confirm the computed affinity. Next, only for the molecules that show high in vitro affinity, the intrinsic activity should be evaluated in order to discriminate between agonist ($\alpha = 1$), partial agonist ($1 < \alpha < 0$), or antagonist ($\alpha = 0$).

Our in silico approach can thus compute the affinity of the simulated complexes, whereas reliable values for intrinsic activity ($\alpha$) can be obtained only by in vitro and/or in vivo tests [37,38]. Nowadays, several in vitro tests aim at evaluating the affinity of chemicals for ARs, such as the AR Binding Assay described in OCSPP Guideline 890.1150 and proposed by the EPA [39] as part of the Tier 1 of the Endocrine Disruptor Screening Program (EDSP). This test consists of a radioligand binding assay that identifies compounds able to compete for AR binding in vitro, and is not meant to measure the molecular intrinsic activity ($\alpha$) and to classifying them as (partial) agonists or antagonists.

Tests aimed at the evaluation of the intrinsic activity ($\alpha$) of putative EASs are mainly based on two end points: the measurement of cell proliferation or the use of an androgen-responsive reporter gene. The A-SCREEN assay [40] measures the proliferation of sensitive cells to screen for androgen activity. The MDA-kb-2 cell line has been developed by scientists at the EPA [41] through a stable transfection of AR and the insertion of an MMTV-driven luciferase reporter gene into the human mammary cancer MDA-MB-455 cell line. Both androgen and glucocorticoid agonists can activate the MMTV luciferase gene, and antagonists can be tested with respect to a fixed reference concentration of the agonist.

| Letter (Fig. 1) | Natural ligand | Relative binding affinity | $\Delta G$-MD kcal/mol | Computed $K_i$ | $\alpha$ | $K_i$ |
|----------------|----------------|--------------------------|-----------------------|---------------|--------|-------|
| B              | DHT            | 100                      | -12.52                | 1.6 $\times$ 10$^{-9}$ | 1       | $K_i$ |
| S              | cyproterone acetate | 14                     | -12.47                | 1.5 $\times$ 10$^{-9}$ | 1       | $K_i$ |
| T              | flutamide      | 0.058                    | -8.38                 | 2.89 $\times$ 10$^{-6}$ | 1       | $K_i$ |
| L              | procmidone     | 0.065                    | -8.66                 | 2.36 $\times$ 10$^{-6}$ | 1       | $K_i$ |
| V              | (R,S)-procmidone-3-Cl | 0.050              | -8.38                 | 1.44 $\times$ 10$^{-6}$ | 1       | $K_i$ |
| U              | (R,S)-procmidone-NH-COOH | <0.0001       | -8.37                 | 1.44 $\times$ 10$^{-6}$ | 1       | $K_i$ |
| W              | cyclopropane-(COOH)$_2$ | <0.0001     | -6.12                 | 3.19 $\times$ 10$^{-4}$ | 1       | $K_i$ |

$\Delta G$-MD: binding free energy computed through molecular docking.

doi:10.1371/journal.pone.0104822.t004

Table 3. Molecular docking validation dataset and RMSD values between the co-crystallized and the docked ligands.

| Species     | PDB code | Ligand | RMSD (Å) |
|-------------|-----------|--------|----------|
| Human       | 3L3X      | DHT    | 0.17     |
| Human       | 2AMA      | DHT    | 0.24     |
| Human       | 2PIO      | DHT    | 0.26     |
| Human       | 2AM9      | testosterone | 0.13     |
| Human       | 2YHD      | testosterone | 0.26     |
| Human       | 2O27      | cyproterone acetate | 0.35     |
| Chimpanzee  | 1T7R      | DHT    | 0.15     |
| Chimpanzee  | 1T73      | DHT    | 0.14     |
| Rat         | 1137      | DHT    | 0.32     |
| Rat         | 3G0W      | oxazolidin-2-imine | 0.30     |

doi:10.1371/journal.pone.0104822.t003

Table 4. Experimental (from [27]) and in silico (computed) dissociation constants for the selected compounds with respect to rat AR binding site.
We carried out a validation of the molecular modelling and docking procedures we had devised by comparing experimental and computed dissociation constants ($K_i$) for the human, rat and zebrafish endogenous hormones with respect to their ARs. A high in silico affinity between the endogenous ligands and their specific receptors was observed.

![Box plot for all the calculated binding free energies.](https://example.com/figure4.png)

**Figure 4.** Box plot for all the calculated binding free energies. The yellow boxes represent the binding free energies of the vinclozolin and its metabolites for each species. The red boxes represent the binding free energies of iprodione and its metabolites for each species. The blue boxes represent the binding free energies of procymidone and its metabolites for each species. Outliers are marked as circles. Binding free energies of the endogenous hormones are marked with continuous lines. doi:10.1371/journal.pone.0104822.g004

| Species   | Natural ligand       | DS kcal/mol | $\Delta G$-LM kcal/mol | $\Delta G$-MD kcal/mol | $K_i$ (from MD) | Experimental $K_i$ |
|-----------|----------------------|-------------|------------------------|------------------------|----------------|--------------------|
| human     | testosterone [45]    | -10.30      | -12.08                 | -12.49                 | 1.55 x 10^{-9} | Low nM range       |
| human     | DHT [46]             | -9.11       | -11.10                 | -12.08                 | 7.76 x 10^{-8} | 1.3 x 10^{-9} ± 0.2 x 10^{-9} |
| human     | DHT [47]             | -9.11       | -11.10                 | -12.08                 | 7.76 x 10^{-8} | 2.3 x 10^{-10} ± 0.4 x 10^{-10} |
| zebrafish | testosterone [28]    | -10.21      | -12.06                 | -12.19                 | 9.35 x 10^{-8} | 1.70 x 10^{-9} ± 0.50 x 10^{-9} |
| zebrafish | 11-ketotestosterone [28] | -10.29     | -12.09                 | -10.93                 | 1.11 x 10^{-8} | 4.77 x 10^{-10} ± 2.26 x 10^{-10} |
| rat       | testosterone         | -10.40      | -12.25                 | -12.81                 | 2.67 x 10^{-9} | NA                 |
| rat       | DHT [48]             | -10.97      | -12.37                 | -12.52                 | 1.64 x 10^{-9} | 2.7 x 10^{-10}     |

**Table 5.** Experimental (from literature) and in silico (computed) dissociation constants for the three endogenous tested hormones.

DS: Docking Score; $\Delta G$-LM: binding free energy computed through low-mode molecular dynamics simulations; $\Delta G$-MD: binding free energy computed through molecular docking; $K_i$: dissociation constant computed from molecular docking data.

doi:10.1371/journal.pone.0104822.t005
ARs is a condition sine qua non for applying our selected approach to the investigated problem.

Experimental data available from scientific reports are associated with very high standard error of the mean. Computed binding free energies are evaluated from the analysis of specific ligand-receptor non-covalent interactions; their occurrence is associated with a score that can be interpolated on an experimental curve [42]. We have already reported that the use of empirical scoring functions for estimating dissociation constant values has accuracy in the range of one order of magnitude [43]. Furthermore, the specific ligand-induced activation mechanism of nuclear steroid receptors is based on a conformational transition, leading to the rearrangement of helix 12 [32,33], which seemingly traps the ligand inside the binding site. Accordingly, the experimentally measured $K_i$ have very low apparent values (corresponding to most favourable affinities). Conversely, the $K_i$ values obtained through our in silico approach do not take into account such a displacement. This structural rearrangement is peculiar of nuclear steroid receptors, and should not be confused with the ligand-induced-fit process, which characterizes all the ligand-receptor interaction events. No induced-fit protocols [44] have been implemented in this investigation, since the ligand binding sites of the selected receptors were already well defined in the available crystallographic structures.

In this paper, our model was used to study the affinity of three fungicides (vinclozolin, iprodione and procymidone), as well as of

| Letter (Fig. 1) | Molecule       | Human DS kcal/mol | Rat DS kcal/mol | Zebrafish DS kcal/mol |
|---------------|----------------|-------------------|-----------------|-----------------------|
| D             | (R)-vinclozolin| −9.61             | −8.22           | −9.12                 |
| D             | (S)-vinclozolin| −9.87             | −8.18           | −8.73                 |
| E             | (R)-vinclozolin_1| −10.80          | −8.82           | −9.86                 |
| E             | (S)-vinclozolin_1| −10.44          | −8.83           | −10.23               |
| F             | (R)-vinclozolin_2| −9.46           | −7.96           | −8.94                 |
| F             | (S)-vinclozolin_2| −9.82           | −7.92           | −8.65                 |
| G             | (R,R)-vinclozolin_5| −10.04         | −8.62           | −9.04                 |
| G             | (R,S)-vinclozolin_5| −10.01         | −8.66           | −9.74                 |
| G             | (S,R)-vinclozolin_5| −10.28         | −8.57           | −9.26                 |
| G             | (S,S)-vinclozolin_5| −9.94          | −8.62           | −9.05                 |
| H             | iprodione     | −11.35           | −8.94           | −9.74                 |
| I             | iprodione_8    | −9.18            | −7.71           | −8.93                 |
| J             | iprodione_13   | −8.38            | −6.93           | −8.38                 |
| K             | iprodione_14   | −8.99            | −7.21           | −8.58                 |
| L             | procymidone   | −9.27            | −8.31           | −8.49                 |
| M             | (R,R)-procymidone_1| −9.86         | −9.51           | −9.94                 |
| M             | (R,S)-procymidone_1| −10.56         | −9.44           | −10.24               |
| M             | (S,R)-procymidone_1| −10.20         | −9.35           | −10.35               |
| M             | (S,S)-procymidone_1| −10.31         | −9.60           | −9.75                 |
| N             | (R,R)-procymidone_2| −9.83          | −8.87           | −10.47               |
| N             | (R,S)-procymidone_2| −10.17         | −9.17           | −9.85                 |
| N             | (S,R)-procymidone_2| −10.09         | −8.97           | −10.17               |
| N             | (S,S)-procymidone_2| −10.21         | −9.19           | −10.24               |
| O             | (R,R)-procymidone_3| −9.96          | −9.67           | −11.06               |
| O             | (R,S)-procymidone_3| −9.91          | −9.50           | −9.36                 |
| O             | (S,R)-procymidone_3| −9.53          | −9.15           | −9.84                 |
| O             | (S,S)-procymidone_3| −10.22         | −9.22           | −10.15               |
| P             | procymidone_4   | −9.74            | −8.49           | −8.52                 |
| Q             | procymidone_5   | −9.54            | −8.37           | −8.63                 |
| R             | (R)-procymidone_6| −10.29           | −9.65           | −10.23               |
| R             | (S)-procymidone_6| −10.28           | −9.58           | −10.48               |
| A             | testosterone   | −10.30           | −10.40          | −10.21               |
| B             | DHT            | −9.11            | −10.97          | −               |
| C             | 11-ketotestosterone| −             | −              | −10.29               |

The last three rows contain the DS values for the endogenous hormones in each species.

The doi:10.1371/journal.pone.0104822.t006

Table 6. Docking Score (DS) (kcal/mol) for the top scoring poses (protein-ligand complexes) for all the compounds of the tested database.
their metabolites, with respect to the AR LBD of three different species (human, rat and zebrafish). These molecules were selected because of their classification in the same chemical group (dicarboximides) as well as of their classification as EASs. The mechanism behind the endocrine effects of both vinclozolin [10] and procymidone [16] is well-documented. They compete with the endogenous hormones for the binding to the AR, but they...
cannot activate it, because of their low intrinsic activity ($\alpha = 0$), and thus exert antiandrogenic effects. The toxic mechanism of iprodione has not been fully clarified yet and this compound is classified sometimes as antiandrogenic [16] sometimes as androgenic agent [14]. From our results, it is clear that all the tested fungicides and their metabolites can bind AR and compete

**Figure 7. Hazard evaluation pipeline for putative androgen disruptors.** Step 1: database production; step 2: *in silico* binding assay; step 3 *in vitro* binding assay for the selected dataset; step 4: *in vitro* activity assays only for the high affinity molecules (positive hits); and identification of agonist ($\alpha = 1$), partial agonist ($1 < \alpha < 0$) and antagonist ($\alpha = 0$) activity. doi:10.1371/journal.pone.0104822.g007
with the endogenous hormones in all the tested species, exerting antiandrogenic effects.

In detail, in human and zebrafish, the tested compounds and metabolites can bind AR LBD with affinities comparable to the endogenous hormones: this suggests that there is a strong competition to occupy the binding site. On the contrary, the rat AR shows a lower affinity for the tested compounds, and - as a single assay – it is thus not a suitable molecular model to assess the toxicity of EASs and of their derivatives. However, identifying a toxic molecule in rat is an important alert signal, because this compound is likely to have an even stronger impact in humans.

Conclusions

Our results shed a new light on the selection of the in vitro tests used for EAS hazard identification. Actually, rat seems to be less sensitive than human to the tested putative EASs. In vitro tests based on rat preparations could underestimate the sensitivity to these classes of molecules, differently from the human AR. On the other hand, zebrafish could be a more reliable model than rat, especially for environmental effects. For these reasons, the human AR LBD seems the most reliable target to be considered for estimating the EAS hazard in humans, whereas the zebrafish AR LBD should be considered, when environmental effects of EAS have to be investigated.

Our in silico approach emerges as a computational methodology for the evaluation of the AR affinity (prioritization of assessment) of a large number of molecules. During the design of new chemicals, the molecules that show highest affinities should in principle be disregarded and the main efforts should be focused on the molecules that show the lowest affinities. On the contrary, during a safety evaluation process, attention should be focused on the molecules that show the highest affinities.

While the in silico screening cannot be used as a stand-alone procedure, it can be successfully used as a first prioritizing step in a tier approach (Figure 7). The second mandatory check for the in silico positive hits should be an in vitro evaluation procedure, in which the affinity of the positive hits are measured through a reference cellular assay. From our results, the choice of the species to use in competitive binding assay should be carried out carefully, because it may lead to hazard over-underestimation.

Supporting Information

File S1 The Supporting Information file contains:

Figure S1. Global alignment between primary structures of zebrafish and chimpanzee AR LBDs. Figure S2. Docking Score plot for the 1,000 non-interacting randomly selected compounds. Figure S3. Interaction network for DHT in the 3L3X crystallographic structure. (DOCX)

Author Contributions

Conceived and designed the experiments: IE CLG. Performed the experiments: AF CS CP. Analyzed the data: IE CLG MM CS. Contributed reagents/materials/analysis tools: IE. Contributed to the writing of the manuscript: IE CLG MM CS AF CP.

References

1. European Parliament (2006) Regulation (EC) No. 1907/2006 of the European Parliament and the Council of 18 December 2006 concerning the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH). OJL 396.
2. European Parliament (2009) Regulation (EC) No. 1107/2009 of the European Parliament and the Council of 21 October 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEG and 91/414/EEC. OJL 309.
3. European Parliament (1998) Directive, 1998. 98/8/EC of the European Parliament and the Council of 16 February 1998 concerning the placing on the pacing of biocidal products on the market. OJL 123.
4. European Parliament (2009) Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products OJL 342: 59.
5. European Parliament (2000) Directive 2000/60/EC of the European Parliament and of the Council of 23 October 2000 establishing a framework for Community action in the field of water policy. OJL 327: 72.
6. Bars R, Fegert I, Gross M, Lewis D, Weltje L, et al. (2012) Risk assessment of new chemicals, the molecules that show highest affinities should be investigated.
7. Gibson JE (2010) An integrated summary of commentary on the National Academy of Sciences report on “Toxicity testing in the 21st century: a vision and a strategy”. Hum Exp Toxicol 29: 33–55.
8. Eberini I, Daniele S, Parravicini C, Seni C, Trincavelli ML, et al. (2011) In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des 25: 743–752.
9. Shikha P, Madhur M, Raja SD, Mohammed HS (2013) In silico designing of a potent analogue against HIV-1 Nef protein and protease by predicting its interaction network with host cell proteins. Journal of Pharmacy And Bioallied Sciences 5.
10. Kecsk M, Wilson EM (1997) Environmental antiandrogenic developmental effects, molecular mechanisms, and clinical implications. J Mol Med (Berl) 75: 198–207.
11. Tarui H, Abe J, Tomihara Y, Kawamura S, Kaneko H (2009) Metabolism of procymidone derivatives in female rats. J Agric Food Chem 57: 10683–10688.
12. Sierra-Santoyo A, Angelus-Soto E, López-González MI, Harrison RA, Hughes D (2011) In vitro metabolism of the anti-androgenic fungicide vinclozolin by rat liver microsomes. Archives of Toxicology 86.
13. Buszynska-Jarzyna A, Debrenne F, Perdu E, Jouannin I, Jarp JP, et al. (2008) Biotransformation of vinclozolin in rat. Journal of Chromatography B 856: 4832–4839.
14. Blystone CR, Lambrecht CS, Furr J, Wilson VS, Gray LE (2007) Iprodione delays male rat pubertal development, reduces serum testosterone levels, and decreases ex vivo testicular testosterone production. Toxicology Letters 174: 74–81.
15. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, et al. (2009) Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement. Endocrine Reviews 30: 293–342.
16. Kortenkamp A, Martin O, Faust M, Evans R, McKinlay R, et al. (2011) State of the Art Assessment of Endocrine Disrupters.
17. Uznun M, Suzuki H, Skinner MK (2004) Effect of the anti-androgenic endocrine disruptor vinclozolin on embryonic testis cord formation and postnatal testis development and function. Reproductive Toxicology 18: 765–774.
18. Yu WJ, Lee BJ, Nam SY, Aun B, Hong JT, et al. (2004) Reproductive disorders in pubertal and adult phase of the male rats exposed to vinclozolin during puberty. J Vet Med Sci 66: 847–853.
19. Yao Z, Lin Z, Wang T, Tian D, Zou X, et al. (2013) Using molecular docking-based binding energy to predict toxicity of binary mixture with different binding affinities. Chemosphere 92: 1169–1174.
20. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157–1174.
21. Hur E, Palf SJ, Payne ES, Gron H, Barheer BM, et al. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2: E274.
22. Labute P (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29: 1693–1698.
23. Edelhochrner H, Facello M, Fu P, Lioung J (1995) Proceedings of 20th Hawaii International Conference on System Science Measuring proteins and voids in proteins.
24. Wojciechowski M, Lesyng B (2004) Generalized born model: analysis based binding energy to predict toxicity of binary mixture with different binding sites. Chemosphere 92: 1169–1174.
25. Hur E, Palf SJ, Payne ES, Gron H, Barheer BM, et al. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2: E274.
26. Labute P (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29: 1693–1698.
27. Edlebrunner H, Facello M, Fu P, Lioung J (1995) Proceedings of 20th Hawaii International Conference on System Science Measuring proteins and voids in proteins.
28. Wojciechowski M, Lesyng B (2004) Generalized born model: analysis based binding energy to predict toxicity of binary mixture with different binding sites. Chemosphere 92: 1169–1174.
29. Hur E, Palf SJ, Payne ES, Gron H, Barheer BM, et al. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biol 2: E274.
30. Labute P (2008) The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J Comput Chem 29: 1693–1698.
31. Edlebrunner H, Facello M, Fu P, Lioung J (1995) Proceedings of 20th Hawaii International Conference on System Science Measuring proteins and voids in proteins.
29. Chang CS, Kokontis J, Liao ST (1988) Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci U S A 85: 7211–7215.

30. D’Ursi P, Salvi E, Fossa P, Milanesi L, Rovida E (2005) Modelling the interaction of steroid receptors with endocrine disrupting chemicals. BMC Bioinformatics 6 Suppl 4: S10.

31. Wu B, Ford T, Gu JD, Zhang XX, Li AM, et al. (2010) Computational studies of interactions between endocrine disrupting chemicals and androgen receptor of different vertebrate species. Chemosphere 80: 335–341.

32. Watanabe C, Watanabe H, Tanaka S (2010) An interpretation of positional displacement of the helix12 in nuclear receptors: preexistent swing-up motion triggered by ligand binding. Biochim Biophys Acta 1804: 1832–1840.

33. Brozowski AM, Pike AC, Dauter Z, Hubbard RE, Bunn T, et al. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389: 753–756.

34. Bohl CE, Wu Z, Miller DD, Bell CE, Dalton JT (2007) Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 282: 13648–13655.

35. Krewezi D, Acosta D Jr, Andersen M, Anderson H, Bailar JC 3rd, et al. (2010) Toxicity testing in the 21st century: a vision and a strategy. J Toxicol Environ Health B Crit Rev 13: 51–138.

36. Borgert CJ, Sargent EV, Casella G, Dietrich DR, McCarty LS, et al. (2012) The human relevant potency threshold: reducing uncertainty by human calibration of cumulative risk assessments. Regul Toxicol Pharmacol 62: 313–328.

37. Bauer ER, Meyer HH, Stahlshimn-Alpern P, Sauerwein H (1998) Application of an androgen receptor assay for the characterisation of the androgenic or antiandrogenic activity of various phenylurea herbicides and their derivatives. Analyst 123: 2405–2417.

38. Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, et al. (1994) Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 48: 111–119.

39. US Environmental Protection Agency (2011) Androgen Receptor Binding (Rat Ventral Prostate Cytosol). Standard Evaluation.

40. Soto AM, Maffini MV, Schaeberle CM, Sonnenschein C (2006) Strengths and weaknesses of in vitro assays for estrogenic and androgenic activity. Best Pract Res Clin Endocrinol Metab 20: 15–33.

41. Wilson VS, Bilewicz K, Lambricht CR, Gray LE Jr (2002) A novel cell line, MDA-akb2, that stably expresses an androgen- and glucocorticoid-responsive reporter for the detection of hormone receptor agonists and antagonists. Toxicol Sci 66: 69–81.

42. Meng XY, Zhang HX, Mezei M, Cui M (2011) Molecular Docking: A Powerful Approach for Structure-Based Drug Discovery. Current Computer-Aided Drug Design 7: 146–157.

43. Eberini I, Rocco AG, Mantegazza M, Gianazza E, Baroni A, et al. (2008) Computational and experimental approaches assess the interactions between bovine beta-lactoglobulin and synthetic compounds of pharmacological interest. J Mol Graph Model 26: 1004–1013.

44. Sotriffer CA (2011) Accounting for induced-fit effects in docking: what is possible and what is not?Curr Top Med Chem 11: 179–191.

45. Pereira de Jesus-Tran K, Cote PL, Cantin I, Blanchet J, Labrie F, et al. (2006) Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci 15: 987–999.

46. Muecheler EK (1987) The androgen receptor of the human endometrium. Endocrine Research 13.

47. Mowszowic I, Irene M, Wright F, Bouchard P, Kuttenin F, et al. (1980) Androgen receptor in human skin cytosol. The Journal of Clinical Endocrinology & Metabolism.

48. Hosokawa S, Murakami M, Ineyama M, Yamada T, Yoshitake A, et al. (1992) The affinity of procyomide to androgen receptor in rats and mice. The Journal of Toxicological Sciences 18.